Your browser doesn't support javascript.
loading
TRIB3 promotes MYC-associated lymphoma development through suppression of UBE3B-mediated MYC degradation.
Li, Ke; Wang, Feng; Yang, Zhao-Na; Zhang, Ting-Ting; Yuan, Yu-Fen; Zhao, Chen-Xi; Yeerjiang, Zaiwuli; Cui, Bing; Hua, Fang; Lv, Xiao-Xi; Zhang, Xiao-Wei; Yu, Jiao-Jiao; Liu, Shan-Shan; Yu, Jin-Mei; Shang, Shuang; Xiao, Yang; Hu, Zhuo-Wei.
Afiliación
  • Li K; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, the Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China.
  • Wang F; NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Yang ZN; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Zhang TT; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Yuan YF; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Zhao CX; Anyang Tumor Hospital, Henan University of Science and Technology, 300020, Anyang, China.
  • Yeerjiang Z; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Cui B; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Hua F; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Lv XX; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Zhang XW; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Yu JJ; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Liu SS; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Yu JM; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Shang S; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Xiao Y; Immunology and Cancer Pharmacology Group, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
  • Hu ZW; National Clinical Research Center for Metabolic Disease, Department of Metabolism and Endocrinology, the Second Xiangya Hospital, Central South University, 410011, Changsha, Hunan, China.
Nat Commun ; 11(1): 6316, 2020 12 09.
Article en En | MEDLINE | ID: mdl-33298911
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Represoras / Linfoma no Hodgkin / Proteínas Proto-Oncogénicas c-myc / Proteínas Serina-Treonina Quinasas / Proteínas de Ciclo Celular / Ubiquitina-Proteína Ligasas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2020 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Represoras / Linfoma no Hodgkin / Proteínas Proto-Oncogénicas c-myc / Proteínas Serina-Treonina Quinasas / Proteínas de Ciclo Celular / Ubiquitina-Proteína Ligasas Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2020 Tipo del documento: Article País de afiliación: China